


## Cardiac Lecture Series #2: Cardiac Warning Signs

November 1, 2022



- Next Maternal Webinar <u>December 6<sup>th</sup></u> Topic: Cardiomyopathy | Speaker: Charisma Manley, MD
- GaPQC Perinatal Improvement Coordinator Amy Stratton
- Quality Improvement Support Shane Reed
- Cardiac Initiative Onboarding
- GaPQC Data Transition to Survey 123







### Natalie Poliektov, DO, MS Department of Gynecology and Obstetrics Emory School of Medicine

.

## Cardiac Warning Signs

Natalie Poliektov, DO, MS Emory Gyn/Ob PGY-3



November 1, 2022 2:00 - 3:00 PM



**Department of Gynecology** and Obstetrics



## Disclosures

### **External Industry Relations**

Equity, stock or options in biomedical indus publishers


**Board of Directors or office** 

Royalties from Emory or from exter


Industry funds to Emory for my re

Other

ships	Company	Role
stry companies or	None	None
er	None	None
ernal entity	None	None
esearch	None	None
	None	None









## Learning Objectives


Understand cardiovascular changes in pregnancy

Recognize the red flags of cardiac pathology


**Confidently** manage pregnant and postpartum cardiac patients

### Review Background and cardiovascular significance physiology in pregnancy

## Outline



## Background




The most common cause of maternal






### Causes of pregnancy-related death in the United States: 2016-2018





CDC.gov










## Risk factors for CVD-related maternal mortality






**Black women** >3x higher risk of maternal mortality




**8x higher risk** of CVD-related maternal mortality




## **Risk factors for CVD-related** maternal mortality

## 2016-2018



**Black women** >3x higher risk of maternal mortality

> **8x higher risk** of CVD-related maternal mortality



### **Risk factors for CVD-related** maternal mortality

## Barriers

Access to care Quality of care Implicit biases Structural racism Health system barriers Mistrust of medical system Prevalence of chronic diseases





DEATHS

PER 100,000 LIVE BIRTHS



PER 100,000 LIVE BIRTHS




WERE PREVENTABLE PREGNANCY-RELATED



### THE LEADING CAUSE OF DEATHS (PREGNANCY-RELATED) Cardiovascular / Coronary Cardiomyopathy Hemorrhage Infection Cerebrovascular Accidents

### PREGNANCY ASSOCIATED DEATHS BY TIMING OF DEATH IN RELATION **TO END OF PREGNANCY IN GEORGIA**










Adapted from DPH.georgia.gov

### FIGURE 2 Factors contributing to pregnancy-related cardiovascular deaths, California 2002-2006

**Patient Factors** 







## Review of Cardiovascular Physiology

	First Trimester	Second Trimester	Third Trimester	Stage 1 Labor	Stage 2 Labor	Early Postpartum
Cardiac output	↑5–10%	↑↑35–45%	<b>b</b>	↑ <b>30%</b>	↑↑ <b>50%</b>	↑↑↑60–80% immediately, then rapidly decreases within the first hour
Heart rate	↑3–5%	10−15%	↑15 <b>-</b> 20%	During contrac ↑40–50	tions:	↓5—10% within 24 hours; con- tinues to decrease throughout the first 6 weeks
Blood pressure	↓ <b>10%</b>	↓5%	↑ <b>5%</b>	During contract ↑ SBP 15 ↑ DBP 10	tions: 5–25%	↓SBP 5–10% within 48 hours; may increase again between days 3–6 due to fluid shifts

## **Pregnancy lowers threshold for** isolated rhythm disturbances

## Hemodynamic

**Moussa 2019** 




### Increased blood volume: (1100-1600 mL!)

## **1** RBC mass **tt** plasma volume

### **Postpartum:** ~ 500 mL autotransfusion

## Hematologic

### **Dilutional anemia**








## LV mass f 50% and RV mass f 40% LV EDV **1** 10%

### $EF = or \downarrow$

## 20% of women have diastolic dysfunction at term

## Structural






## Hyper-coagulability, venous stasis, I mobility, compression of IVC/pelvic veins



## Coagulation





## Routine Obstetric Management of the Cardiac Patient

## Stratify into risk category

## CARPREG

Prior cardiac event (heart failure, transient ischaemic attack, stroke before pregnancy or arrhythmia).

Baseline NYHA functional class >II or cyanosis.

Left heart obstruction (mitral valve area  $<2 \text{ cm}^2$ , aortic valve area  $<1.5 \text{ cm}^2$ , peak LV out ow tract gradient >30 mmHg by echocardiography).

Reduced systemic ventricular systolic function (ejection fraction <40%).

### Conditions in which pregnancy risk is WHO I

- Uncomplicated, small or mild
- pulmonary stenosis
- patent ductus arteriosus
- mitral valve prolapse

Successfully repaired simple lesions (atrial or ventricular defect, patent ductus arteriosus, anomalous pulmonary drainage).

Atrial or ventricular ectopic beats, isolated

Conditions in which pregnancy risk is WHO II of

WHO II (if otherwise well and uncomplicated)

Unoperated atrial or ventricular septal defect

Repaired tetralogy of Fallot

Most arrhythmias

WHO II-III (depending on individual)

Mild left ventricular impairment

Hypertrophic cardiomyopathy

Native or tissue valvular heart disease not considered

Marfan syndrome without aortic dilatation Aorta <45 mm in aortic disease associated with bicus

Repaired coarctation

### mWHO

	WHO III
	Mechanical valve
	Systemic right ventricle
	Fontan circulation
lar septal y venous	Cyanotic heart disease (unrepaired)
	Other complex congenital heart disease
	Aortic dilatation 40 45 mm in Marfan syndrome
r III	Aortic dilatation 45 50 mm in aortic disease associated with bicuspid aortic valve
	Conditions in which pregnancy risk is WHO IV (pregnancy contraindicated)
	Pulmonary arterial hypertension of any cause
	Severe systemic ventricular dysfunction (LVEF <30%, NYHA III IV)
	Previous peripartum cardiomyopathy with any residual impairment of left ventricular function
	Severe mitral stenosis, severe symptomatic aortic stenosis
IWHO I or IV	Marfan syndrome with aorta dilated >45 mm Aortic dilatation >50 mm in aortic disease associated with bicuspid aortic valve
pid aortic valve	Native severe coarctation

### ZAHARA

### ZAHARA predictors<sup>57</sup>

History of arrhythmia event.

Baseline NYHA functional class >II.

Left heart obstruction (aortic valve peak gradient >50 mm Hg).


Mechanical valve prosthesis.

Moderate/severe systemic atrioventricular valve regurgitation (possibly related to ventricular dysfunction).

Moderate/severe sub-pulmonary atrioventricular valve regurgitation (possibly related to ventricular dysfunction).

Use of cardiac medication pre-pregnancy.

Repaired or unrepaired cyanotic heart disease.



ESG 2011

## mWHO

Class	Maternal Risk Factors	Cardiac Event Rat
	Uncomplicated small/mild pulmonary stenosis, PDA, mitral valve prolapse Successfully repaired simple lesions (ASD, VSD, anomalous pulmonary venous drainage), isolated atrial or ventricular ectopic beats	
	Unrepaired ASD, VSD, repaired Tetrology of Fallot, most arrhythmias	
	Mild LV impairment, HOCM, naive or tissue valvular disease, Marfan syndrome without aortic dilation, aortic dilation < 45 mm in bicuspid aortic valve, repaired coarctation	
	Mechanical valve, systemic RV, Fontan circulation, unrepaired cyanotic heart disease, complex CHD, aortic dilation 40-45 mm in Marfan syndrome, aortic dilation 45-50 mm in bicuspid aortic valve	
	Pulmonary art NYHA class II stenosis, seve syndrome, ad	> 27


### Adapted from Canobbio 2017, Moussa 2019




## NYHA

Class	Symptoms with activity	Symptoms at rest	Functional impairment
	None	None	Normal
	Mild	None	Slight
	Moderate	None	Marked
IV	Severe	Present	Severe


### Fatigue, palpitations, chest pain, dyspnea, syncope







### "Cardio-Obstetrics Team"




## Preconception




**Discontinue teratogenic drugs** 

**Offer reliable contraception** 







### **Manage chronic conditions**


Anesthesia consult

**Genetic counseling** 

Fetal echo/growth scans



Delivery




**Baseline EKG**, echo, labs

Follow up echos as indicated

**Recommendations regarding** exercise/activity

### Most common intrapartum cardiac complications are pulmonary edema or arrhythmias



shunts

### **Moderate-severe** valvular disease

dysfunction

## Intrapartum


valves



## Obstetric meds with cardiac influences

Drug	CV Side Effects	Considerations
Corticosteroids	Fluid retention, HTN, electrolyte disturbances	Use with caution in HF, HTN
Oxytocin	Arrhythmias, hypotension	Titrate carefully and avoid rapid IV bolu
Magnesium	Hypotension, vasodilation, syncope	Titrate carefully in pre-load dependent
Terbutaline	Tachycardia, hypotension, arrhythmias, myocardial ischemia	Avoid in preload-dependent or at risk c arrhythmias
Methergine	Coronary artery vasospasm, HTN, arrhythmias	Avoid in CAD or at risk of arrythmias, aortopathies
Hemabate	HTN, palpitations, tachycardia	Avoid in PAH, pulmonary edema or cyanotic ACHD
TXA		Caution in uncorrected thrombosis- associated CVD

Adapted from Moussa 2019



## Increased risk of maternal morbidity and mortality

## High risk for complications for first 7 days after delivery up to 6 months postpartum






**Vitals** 

## Immediate Postpartum






Exam


**Limit IVF** 





### 7-14 day clinic appointment

## At-home Postpartum








### **3-mo comprehensive** cardiovascular appointment


## At-home Postpartum



Future CVD risk can be reduced 4-13% with healthy lifestyle changes




Workup of Cardiac Complaints



# pregnancy and postpartum





### Many signs and symptoms of heart disease overlap with those of normal pregnancy and postpartum



## **Table 2.** How to Differentiate Common Signs and Symptoms of Normal Pregnancy Versus Those That Are Abnormal and Indicative of Underlying Cardiac Disease



CAUTION*†	STOP <sup>†‡</sup>
Nonemergent Evaluation	Prompt Evaluation Pregnancy Heart Team
None	Yes



## **Table 2.** How to Differentiate Common Signs and Symptoms of Normal Pregnancy Versus Those That Are Abnormal and Indicative of Underlying Cardiac Disease

	ROUTINE CARE	CAUTION*†	STOP <sup>†‡</sup>	
	Reassurance	Nonemergent Evaluation	Prompt Evaluation Pregnancy Heart Team	
Self-reported symptoms Shortness of breath	None or mild No interference with activities of daily living; with heavy exertion only	Yes With moderate exertion, new-onset asthma, persistent cough, or moderate or severe OSA <sup>§</sup>	Yes At rest; paroxysmal nocturnal dyspnea or orthopnea; bilateral chest infiltrates on CXR or refractory pneumonia	
Chest pain	Reflux related that resolves with treatment	Atypical	At rest or with minimal exertion	
Palpitations	Few seconds, self-limited	Brief, self-limited episodes; no lightheadedness or syncope	Associated with near syncope	
Syncope	Dizziness only with prolonged standing or dehydration	Vasovagal	Exertional or unprovoked	
Fatigue	Mild	Mild or moderate	Extreme	





Table 2. How to Differentiate Common Signs and Symptoms of Normal Pregnancy Versus Those That Are Abnormal and Indicative of Underlying Cardiac Disease

	ROUTINE CARE	CAUTION*†	STOP <sup>†‡</sup>	
	Reassurance	Nonemergent Evaluation	Prompt Evaluation Pregnancy Heart Team	
Self-reported symptoms	None or mild	Yes	Yes	
Shortness of breath	No interference with activities of daily living; with heavy exertion only	With moderate exertion, new-onset asthma, persistent cough, or moderate or severe OSA <sup>§</sup>	At rest; paroxysmal nocturnal dyspnea or orthopnea; bilateral ches infiltrates on CXR or refractory pneumonia	
Chest pain	Reflux related that resolves with treatment	Atypical	At rest or with minimal exertion	
Palpitations	Few seconds, self-limited	Brief, self-limited episodes; no lightheadedness or syncope	Associated with near syncope	
Syncope	Dizziness only with prolonged standing or dehydration	Vasovagal	Exertional or unprovoked	
Fatigue	Mild	Mild or moderate	Extreme	

Worsened exercise tolerance Difficulty performing ADLs Worsening chest pain/palpitations/dizziness New onset cough or wheezing Worsening LE edema Inability to lay flat (how many pillows) Unusual weight gain History of cardiac/pulmonary conditions History of substance/cigarette use Seen any providers since giving birth



## **Table 2.** How to Differentiate Common Signs and Symptoms of Normal Pregnancy Versus Those That Are Abnormal and Indicative of Underlying Cardiac Disease


	ROUTINE CARE	CAUTION* <sup>†</sup>	STOP <sup>†‡</sup>	
	Reassurance	Nonemergent Evaluation	Prompt Evaluation Pregnancy Heart Team	
Vital signs	Normal			
HR (beats per minute)	<90	90–119	≥120	
Systolic BP (mm Hg)	120–139	140–159 ≥160 (or symptor low BP)		
RR (per minute)	12-15	16-25	≥25	
Oxygen saturation	>97%	95–97%	<95% (unless chronic)	




## **Table 2.** How to Differentiate Common Signs and Symptoms of Normal Pregnancy Versus Those That Are Abnormal and Indicative of Underlying Cardiac Disease

	ROUTINE CARE	CAUTION* <sup>†</sup>	STOP <sup>†‡</sup>
	Reassurance	Nonemergent Evaluation	Prompt Evaluation Pregnancy Heart Team
Physical examination	Normal		
JVP	Not visible	Not visible	Visible >2 cm above clavicle
Heart	S3, barely audible soft systolic murmur	S3, systolic murmur	Loud systolic murmur, diastolic murmur, S4
Lungs	Clear	Clear	Wheezing, crackles, effusion
Edema	Mild	Moderate	Marked











## Table 2. Normal Electrocardiographic Changes Associated With Pregnancy

Left axis shift is seen, with the greatest shift in the third tri caused by elevation of the diaphragm.

Shortening of the PR, QRS, and QT intervals may accompany the increase in resting heart rate.


Nonspecific ST abnormalities, including segment depression or flattened and inverted T waves in lead III, occur frequently.

## ≥ 1 Symptom + ≥ 1 Vital Signs Abnormal + ≥ 1 Risk Factor or ANY COMBINATION ADDING TO ≥ 4

### **Brain Natriuretic Peptide**

н.				a	
	m	e	S	te	r

Canobbio 2017



California Department of Public Health, 2017, CMQCC







## $\geq$ 1 Symptom + $\geq$ 1 Vital Signs Abnormal + $\geq$ 1 Risk Factor <u>or</u> ANY COMBINATION ADDING TO $\geq 4$

## Obtain: EKG and BNP


Normal level is < 10 pg/mL

Normal in pregnancy is < 20 pg/mL

Adverse maternal cardiac events associated with BNP > 100 pg/mL

Negative predictive indicator: < 100 pg/mL, HF is **unlikely** 

### **Brain Natriuretic Peptide**




California Department of Public Health, 2017, CMQCC










## Obtain: EKG and BNP

- Echocardiogram +/- CXR if HF or valve disease is suspected, or if the BNP levels are elevated 24 hour Holter monitor, if arrhythmia suspected
- Referral to cardiologist for possible treadmill echo vs. CTA vs. alternative testing if postpartum Consider: CXR, CBC, Comprehensive metabolic profile, Arterial blood gas, Drug screen, TSH, etc. Follow-up within 1 week

## $\geq$ 1 Symptom + $\geq$ 1 Vital Signs Abnormal + $\geq$ 1 Risk Factor or ANY COMBINATION ADDING TO $\geq 4$



## Red Flags:



### Shortness of breath at rest


- Severe orthopnea ≥ 4 pillows
- Resting HR ≥120 bpm
- Resting systolic BP ≥160 mm Hg
- Resting RR ≥30
- Oxygen saturations ≤94% with or without personal history of CVD

**PROMPT EVALUATION** and/or hospitalization for acute symptoms

plus

### **CONSULTATIONS** with MFM and Primary Care/Cardiology





### **CONSULTATIONS** with MFM and Primary Care/Cardiology

California Department of Public Health, 2017, CMQCC





## Mortality

## **Pregnancy-related cardiovascular deaths in California: beyond peripartum cardiomyopathy**

Afshan B. Hameed, MD; Elizabeth S. Lawton, MHS; Christy L. McCain, MPH; Christine H. Morton, PhD; Connie Mitchell, MD, MPH; Elliott K. Main, MD; Elyse Foster, MD

Shortnes	s of brea	ath
Ed	ema	
Ches	st pain	
Fat	igue	Tachycardia
Dizz	iness	Hypertension
Whe	ezing	Hypoxia
Palpit	ations	Bilateral crackles/S3
		gallop/heart murmur




# Case Presentations

30 yo G1P0 at 35w0d with history of bicuspid aortic valve presents to ED with chest pain, palpitations, lightheadedness and orthopnea for the past 3 days.

# Case 1

# Case 1

- Vitals: T 37.0, HR 115, RR 22, BP 130/75
- **Exam:** systolic click, harsh systolic murmur, inaudible S2
- Labs: BNP 26 pg/mL, Hgb 10.0 g/dL
- **EKG:** sinus tachycardia, LVH
- **CXR:** enlarged thoracic aorta
- Echo: EF 55-60%, bicuspid aortic valve with severe AS, dilated aortic root 45 mm




# Case 1

She was admitted to the antepartum service, was started on a  $\beta$  blocker and was counseled to avoid strenuous activity. She later underwent an uncomplicated forceps-assisted vaginal birth at 37w0d under epidural anesthesia.

# Bicuspid Aortic Valve


## Most common congenital cardiac malformation! Leading congenital cause of aortic valve stenosis




Autosomal dominant with reduced penetrance and variable expressivity



Stenotic





Valve narrowed and prevents forward flow





- Left-sided stenotic lesions highest risk
  - Preload-dependent
  - Treatment: β blockers, activity restriction, +/- diuretics, anticoagulation






# Valvular Disease

- Regurgitant lesions typically well-tolerated
  - Decreased SVR
  - Risk for pulmonary edema postpartum

Tricuspid Pulmonic Mitral Aortic






40 yo G2P2002 PPD 6 s/p NSVD at 39w1d with history of chronic hypertension, class 2 obesity, and T2DM presents with 10-lb weight gain in 1 week, dyspnea, b/l LE edema.

# Case 2



# Case 2

Vitals: T 37.0, HR 120, RR 34, BP 100/60 **Exam:** Pallor, JVD, 2+ pitting edema **Labs:** BNP 7,062 pg/mL EKG: wnl **CXR:** cardiomegaly, pulmonary edema **Echo:** LV enlargement, decreased contractility, EF 27%



She received aggressive diuresis with IV Lasix and was started on daily Lasix, Metoprolol and Lovenox. 6 months after initial diagnosis, repeat echo showed EF 50%.

# Case 2

# Peripartum Cardiomyopathy

# New-onset systolic dysfunction (EF < 45%) without a reversible cause that presents in last month of pregnancy or up to 5 months postpartum

Incidence	25-100 per 100,000 live births
Risk factors	Multiparity, AMA, multifetal ges
Etiology	Myocarditis, immune, hemodyr
Treatment	Diuretics, β blockers, ACEi/ARE
Prognosis	Depends on LV function at diagno

s in U.S.

station, PIH, African American race


namic stress, cytokines, familial

B, anticoagulation, LVAD, salt/water restriction

osis and within 6 months; 72-90% full recovery



Takeaways



Initiatives

## "GaPQC's AIM will reduce harm related to existing and pregnancy related cardiac conditions through the 4th trimester by 20%"



### AIM **ALLIANCE FOR INNOVATION ON MATERNAL HEALTH**






## Signs Symptoms of Heart Disease

Heart disease is the leading cause of death among women in the U.S. who are pregnant or gave birth in the last 5 months (postpartum). During Pregnancy and Postpartum

## **Symptoms** to watch for in late pregnancy and up to five months postpartum:



**NOTE:** While some of these symptoms are common in late pregnancy, they may be a sign of heart disease especially if they are severe and do not go away after treatment.

www.cmqcc.org




### If you have any of these symptoms and they don't go away:

- Contact your OB, midwife, family medicine doctor, or your primary care provider
- Describe your symptoms clearly and explain how sick you feel
- If your symptoms arise postpartum, be sure to tell the provider that you recently had a baby
- If your provider says your symptoms are normal, ask what symptoms should cause you to call or come back



### Go to the Emergency Department

If you have persistent chest pain or severe shortness of breath, or otherwise feel extremely sick. If possible, take someone with you.





?
2012.
2012.
ted n,
ID X ase.
g/dl
m2
ur
based
ort you.
igh to nelp.
epartment of Health

# References

American Heart Association. Heart valve problems and causes. Last reviewed May 8, 2020. https://www.heart.org/en/health-topics/heart-valve-problems-and-disease/heart-valve-problems-and-causes

Arany Z, Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016;133(14):1397-1409. doi:10.1161/CIRCULATIONAHA.115.020491

Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal Heart Failure. J Am Heart Assoc. 2021;10(14):e021019. doi:10.1161/JAHA.121.021019

Brown KN, Kanmanthareddy A. Heart Transplantation Patient Selection. [Updated 2022 Feb 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537090/

Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017;135(8):e50e87. doi:10.1161/CIR.000000000000458

Centers for disease control and prevention. Pregnancy mortality surveillance system. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. Last reviewed April 13, 2022. <a href="https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm">https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm</a>

Centers for disease control and prevention. Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 US States, 2017–2019. Last reviewed October 5, 2022. https://https://www.cdc.gov/reproductivehealth/maternalmortality/erase-mm/data-mmrc.html

Children's Health. Common types of congenital heart defects. Accessed 5/4/2022. https://www.childrens.com/health-wellness/common-types-of-congenital-heart-defects

Coad F, Frise C. Tachycardia in pregnancy: when to worry?. Clin Med (Lond). 2021;21(5):e434-e437. doi:10.7861/clinmed.2021-0495

Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015;125(1):5-12. doi:10.1097/AOG.00000000000000564

Dasgupta A, Wahed A: Clinical Chemistry, Immunology and Laboratory Quality Control, ch. 8,127-144, DOI: http://dx.doi.org/10.1016/B978-0-12-407821-5.00008-5, 2014 Elsevier Inc.

Dennis AT, Gerstman MD. Management of labour and delivery in a woman with refractory supraventricular tachycardia. Int J Obstet Anesth. 2014;23(1):80-85. doi:10.1016/j.ijoa.2013.08.012

Enriquez AD, Economy KE, Tedrow UB. Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol. 2014;7(5):961-967. doi:10.1161/CIRCEP.114.001517

European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-3197. doi:10.1093/eurheartj/ehr218

Georgia Department of Public Health. Maternal mortality. Last updated 6/9/22. Accessed 10/5/22. https://dph.georgia.gov/maternal-mortality

Giusti B, Sticchi E, De Cario R, Magi A, Nistri S, Pepe G. Genetic Bases of Bicuspid Aortic Valve: The Contribution of Traditional and High-Throughput Sequencing Approaches on Research and Diagnosis. Front Physiol. 2017;8:612. Published 2017 Aug 24. doi:10.3389/fphys.2017.00612

Hameed AB, Lawton ES, McCain CL, et al. Pregnancy-related cardiovascular deaths in California: beyond peripartum cardiomyopathy. Am J Obstet Gynecol. 2015;213(3):. doi:10.1016/j.ajog.2015.05.008

Hameed AB, Morton CH, and A Moore. Improving Health Care Response to Cardiovascular Disease in Pregnancy and Postpartum Developed under contract #11-10006 with the California Department of Public Health, Maternal, Child and Adolescent Health Division. Published by the California Department of Public Health, 2017.

Ibetoh CN, Stratulat E, Liu F, et al. Supraventricular Tachycardia in Pregnancy: Gestational and Labor Differences in Treatment. Cureus. 2021;13(10):e18479. Published 2021 Oct 4. doi:10.7759/cureus.18479

Karafiatova L, Lazarova M, et al. Peripartum cardiomyopathy - a case report and concise review. Cor et vasa. 2017; 59(4):e272-e276. doi:10.1016/j.crvasa.2016.12.013

# References

Lindley KJ, Bairey Merz CN, Asgar AW, et al. Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 2/5. J Am Coll Cardiol. 2021;77(14):1778-1798. doi:10.1016/j.jacc.2021.02.026

Lindley KJ, Verma AK, Blauwet LA. Peripartum Cardiomyopathy: Progress in Understanding the Etiology, Management, and Prognosis. Heart Fail Clin. 2019;15(1):29-39. doi:10.1016/j.hfc.2018.08.004

Lindley KJ, Williams, D. Valvular heart disease in pregnancy. Expert analysis. American College of Cardiology. Feb 12, 2018. <a href="https://www.acc.org/latest-in-cardiology/articles/2018/02/12/07/29/valvular-heart-disease-in-pregnancy">https://www.acc.org/latest-in-cardiology/articles/2018/02/12/07/29/valvular-heart-disease-in-pregnancy</a>

Lloyd-Jones G. Radiology Masterclass. Chest X-ray - mediastinum and hilum aortic enlargement. Oct 2019. Accessed May 23, 2022. https://www.radiologymasterclass.co.uk/gallery/chest/mediastinum\_hilum/thoracic\_aneurysm

Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2020 Jun 9;141(23):e904] [published correction appears in Circulation. 2021 Mar 23;143(12):e792-e793]. Circulation. 2020;141(23):e884-e903. doi:10.1161/CIR.000000000000772

Moussa HN, Rajapreyar I. ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease. Obstet Gynecol. 2019;134(4):881-882. doi:10.1097/AOG.000000000003497

Nanna M, Stergiopoulos K. Pregnancy complicated by valvular heart disease: an update. J Am Heart Assoc. 2014;3(3):e000712. Published 2014 Jun 5. doi:10.1161/JAHA.113.000712

Ramlakhan KP, Johnson MR, Roos-Hesselink JW. Pregnancy and cardiovascular disease. Nat Rev Cardiol. 2020;17(11):718-731. doi:10.1038/s41569-020-0390-z

Ramlakhan KP, Kauling RM, Schenkelaars N, et al. Supraventricular arrhythmia in pregnancy [published online ahead of print, 2022 Jan 27]. Heart. 2022;heartjnl-2021-320451. doi:10.1136/heartjnl-2021-320451

Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32(24):3147–3197.

Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019;105(20):1543-1551. doi:10.1136/heartjnl-2018-313476

Shah SY, Higgins A, Desai MY. Bicuspid aortic valve: Basics and beyond. Cleve Clin J Med. 2018;85(10):779-784. doi:10.3949/ccjm.85a.17069

Siu SC, Colman JM. Heart disease and pregnancy. Heart. 2001;85(6):710-715. doi:10.1136/heart.85.6.710

Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. *Heart*. 2006;92(10):1520-1525. doi:10.1136/hrt.2006.095240

# Thank you!





Questions?



Department of Gynecology and Obstetrics





**Most full-term** spontaneous labor or IOL at 39 weeks


**Planned delivery if mWHO** III-IV


**Scheduled pre-term** delivery in highest risk **Most tolerate NSVD** 

**Operative vaginal delivery if** need to avoid valsalva

**CS if Ehlers Danlos, AR** dilation, aortic dissection, most PAH, severe HF

# Delivery planning





**Regional anesthesia** 

Slowly titrate if risk with hypotension



